MC-15959PP MEDICAL BLUE

Mevopur™ Healthcare Colorants and Formulations: a range of medical grade concentrates and pre-colored formulations for a wide range of polymers used in applications such as remote patient monitoring, circulating blood contact, and invasive devices, with pre-tested biocompatibility according to ISO 10993, change control in place, production certified to ISO 13485-2016 and DMF/MAF files available

Medical: brace stiffeners and endoscopic dissectors rods.

Our health care solutions are designed to solve challenging medical application issues from corrosion and chemical resistance to antimicrobial needs.

Personal care products Lawn & garden tools Outdoor goods Office supplies Footwear Houseware durables PCR grade is formulated with recycled ocean plastics Supports the circular economy Can be overmolded to PP Comparable performance to traditional TPEs Versaflex™ Versaflex materials offer the benefits of overmolding and vibration damping to a wide range of end user applications such as medical tubing, protective film, electronics and many others.

Pipes, tubing, fluid management, electrical connectors, battery components, under-the-hood fuel/chemical contact components, non-structural interior components, oil and gas components

Corporations are not exempt from backup withholding with respect to attorneys’ fees or gross proceeds paid to attorneys, and corporations that provide medical or health care services are not exempt with respect to payments reportable on Form 1099-MISC. Barter exchange transactions and patronage dividends Exempt payees 1 through 4 Payments over $600 required to be reported and direct sales over $5,0001 Generally, exempt payees 1 through 52 Payments made in settlement of payment card or third party network transactions Exempt payees 1 through 4 1 See Form 1099-MISC, Miscellaneous Income, and its instructions. 2 However, the following payments made to a corporation and reportable on Form 1099-MISC are not exempt from backup withholding: medical and health care payments, attorneys’ fees, gross proceeds paid to an attorney reportable under section 6045(f), and payments for services paid by a federal executive agency. Other payments” include payments made in the course of the requester’s trade or business for rents, royalties, goods (other than bills for merchandise), medical and health care services (including payments to corporations), payments to a nonemployee for services, payments made in settlement of payment card and third party network transactions, payments to certain fishing boat crew members and fishermen, and gross proceeds paid to attorneys (including payments to corporations). 5.

Operating Income $3,783 $4,100 2020PF 2021E Adjusted EPS (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition Previous Guidance Current Guidance $3,783 $4,300 2020PF 2021E $308 $360 2020PF 2021E $308 $410 2020PF 2021E $1.93 $2.40 2020PF 2021E $1.93 $2.80 2020PF 2021E (1) (1)(1) (1)(1) (1) (in millions) (in millions) 12 BALANCE SHEET • Deleveraging to 1.9x net debt to adjusted EBITDA by the end of 2021 • Driven by record adjusted EBITDA performance and strong free cash flow generation from asset light business • Future cash deployment: M&A, opportunistic share repurchases and balance sheet / continued leverage reduction 3.5x 2.7x 1.9x 2019PF 2020PF 2021E Net Debt / Adjusted EBITDA (1) (1) ($ in m illions) 2021E Adjusted EBITDA 560$ Free Cash Flow 275$ Total Debt 1,860 Less: Cash (800) Net Debt 1,060$ 2021E Net Debt / Adjusted EBITDA 1.9x (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition S U S TA I NA B I L I T Y • Most recent Sustainability report substantially expanded disclosure on key environmental and social topics

Morgan • New Senior Secured Term Loan B and new Senior Unsecured Notes • Potential proceeds from sale of Distribution business modeled to pay off 5.25% senior notes due 2023 and Term Loan • Acquisition aligned with Avient’s track record of disciplined capital allocation policy • Existing dividend policy maintained, focus on deleveraging in the near term (1) (1) Pro forma for the acquisition of Dyneema® and potential divestiture of Distribution, including repayment of senior notes due 2023 and Term Loan Cash and Cash Equivalents 595$ Senior Secured Term Loan due 2026 605$ New Senior Secured Term Loan B 500 Total Senior Secured Debt 1,105$ Senior Unsecured Notes due 2025 650$ New Senior Unsecured Notes 740 Total Senior Unsecured Debt 1,390$ Total Debt 2,495$ Net Debt 1,900$ 2022 Pro forma Adjusted EBITDA 660$ Net Debt / Adjusted EBITDA 2.9x Pro Forma Capitalization (2022 estimates, all figures in $M) T WO - Y E A R L E V E R AG E G OA L 24 3.5x 2.7x 1.7x 2.9x 2.5x 2.2x 2019PF 2020PF 2022E 2022PF 2023E 2024E Dyneema® AcquisitionClariant Color Acquisition (1) Pro forma for the acquisition of the Clariant Color business (2) Pro forma for the acquisition of Dyneema® and potential divestiture of Distribution, including repayment of senior notes due 2023 and Term Loan (1) (1) (2) 25 P RO F O R M A M O D E L I N G 2022E Pro Forma Pro Forma ($M) w/ Dyneema w/Sale Revenue 5,100$ 415$ 5,515$ (1,775)$ 3,740$ Adjusted EBITDA 635 130 765 (105) 660 EBITDA % 12% 31% 14% 6% 18% Pro Forma EPS (Adjusted) 3.50$ 0.00$ 3.50$ (0.56)$ 2.94$ Pro Forma EPS (excl. amortization) 3.96$ 0.35$ 4.31$ (0.56)$ 3.75$ Leverage (12/31/2022E) Net Debt / Adjusted EBITDA 1.7x 3.5x 2.9x Avient Dyneema Distribution® ® OUR SPECIALTY JOURNEY AC Q U I S I T I O N H I S TO RY 27 Commercial Resources(1) Operating Income ($ in millions) Operating Margins 259 360 At Acquisition 2021 $40 $122 At Acquisition 2021 9% 21% At Acquisition 2021 Established Acquisitions (> 7 years) + 39% + 210% + 1200 bps (1) Commercial Resources include associate headcount in R&D / Technical, Marketing and Sales C L A R I A N T C O LO R AC Q U I S I T I O N 28 $133 $205 2019PF 2021 28 Clariant Color EBITDA Growth Purchase Price Multiple 10.8x 7.0x 6.1x 2019PF 2021 2021 w/ Full Synergies • Acquisition of Clariant Color business significantly expanded presence in healthcare, packaging and consumer end markets • Strength of portfolio – double-digit annual EBITDA growth since acquisition • $54 million of synergies realized in 2021 • Acquisition completed on July 1, 2020 for $1.45 billion.

This document is property of Avient Corporation and may not be reproduced or communicated to third parties without authorization. 12.0 Quality Details & Revision Control Definitions and Acronyms Term Definition ISO International Standards Organization QMS Quality Management System LSS Lean Six Sigma FDM Food, Drug, Medical GMP Good Manufacturing Practices TSCA Toxic Substance Control Act Food Allergens Food Allergens Include; Soy, Shellfish, Egg, Peanut, and Dairy CoA Certificate of Analysis CoC Certification of Conformance BoL Bill of Lading IATF International Automotive Task Force NDA Non-Disclosure Agreement ISO 9001 : 2015 Quality Management system requirements IATF 16949 : 2016 Quality management system requirements for automotive production and relevant service parts organization ISO 13485 : 2016 Medical devices—quality management systems requirements for regulatory purposes